Elsevier

The Lancet

Volume 344, Issue 8930, 22 October 1994, Pages 1125-1127
The Lancet

Short reports
Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis

https://doi.org/10.1016/S0140-6736(94)90632-7Get rights and content

Abstract

Our in-vitro, animal, and early clinical data suggest that tumour necrosis factor α (TNFα) is an important target for specific biological therapy in rheumatoid arthritis. We report the results of repeated treatment with a chimeric monoclonal antibody to TNFα (cA2) in patients having disease flares. 7 patients originally enrolled in an open-label trial completed two to four cycles, each of which was followed by a good clinical response, with median improvements in the swollen-joint count and C-reactive protein exceeding 80%. cA2 may be useful therapy in the control of acute disease flares in rheumatoid arthritis and treatment programmes including cA2 may be effective in the long-term management of this disease.

References (9)

There are more references available in the full text version of this article.

Cited by (0)

View full text